# Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis

> **NCT05725057** · PHASE1,PHASE2 · COMPLETED · sponsor: **Artax Biopharma Inc** · enrollment: 31 (actual)

## Conditions studied

- Psoriasis
- Plaque Psoriasis

## Interventions

- **DRUG:** AX-158
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05725057
- **Lead sponsor:** Artax Biopharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-30
- **Primary completion:** 2024-09-04
- **Final completion:** 2024-10-04
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05725057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05725057, "Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05725057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*